Ho Lun Wong, PhD, BScPharm
- Hybrid or lipid-based nanotechnology: Design, evaluation and optimization of lipidpolymer hybrid nanocarriers or lipid-based nanocarriers for sustained, controlled and targeted delivery of therapeutic oligonucleotides (e.g. RNAi agents) and small molecule compounds (e.g. poorly water-soluble novel molecules and chemo agents).
- Strategically merging the “old” and “new”: Develop advanced nanomedicine-based therapeutic strategies for novel combination treatment (e.g. chemo-gene; chemomolecular targeting agent) of malignant diseases, with emphasis on drug-resistant, metastatic prostate cancer, breast cancer and ovarian cancer.